NO964543L - Apolipoprotein E polymorfisme og behandling av Alzheimers sykdom - Google Patents

Apolipoprotein E polymorfisme og behandling av Alzheimers sykdom

Info

Publication number
NO964543L
NO964543L NO964543A NO964543A NO964543L NO 964543 L NO964543 L NO 964543L NO 964543 A NO964543 A NO 964543A NO 964543 A NO964543 A NO 964543A NO 964543 L NO964543 L NO 964543L
Authority
NO
Norway
Prior art keywords
pct
apolipoprotein
polymorphism
alzheimer
disease
Prior art date
Application number
NO964543A
Other languages
English (en)
Norwegian (no)
Other versions
NO964543D0 (no
Inventor
Judes Poirier
Original Assignee
Univ Mcgill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mcgill filed Critical Univ Mcgill
Publication of NO964543D0 publication Critical patent/NO964543D0/no
Publication of NO964543L publication Critical patent/NO964543L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
NO964543A 1994-04-27 1996-10-25 Apolipoprotein E polymorfisme og behandling av Alzheimers sykdom NO964543L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9408465A GB9408465D0 (en) 1994-04-27 1994-04-27 Apolipoprotein e polymorphism & treatment of alzheimer's disease
PCT/CA1995/000240 WO1995029257A2 (en) 1994-04-27 1995-04-26 Apolipoprotein e polymorphism and treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
NO964543D0 NO964543D0 (no) 1996-10-25
NO964543L true NO964543L (no) 1996-12-20

Family

ID=10754293

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964543A NO964543L (no) 1994-04-27 1996-10-25 Apolipoprotein E polymorfisme og behandling av Alzheimers sykdom

Country Status (13)

Country Link
US (1) US5935781A (de)
EP (1) EP0804615B1 (de)
JP (1) JP3285585B2 (de)
AT (1) ATE247717T1 (de)
AU (1) AU693193B2 (de)
CA (1) CA2188933C (de)
DE (1) DE69531557T2 (de)
FI (1) FI964284A7 (de)
GB (1) GB9408465D0 (de)
MX (1) MX9605176A (de)
NO (1) NO964543L (de)
NZ (1) NZ284412A (de)
WO (1) WO1995029257A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7049078B2 (en) * 1994-04-27 2006-05-23 Judés Poirier Apolipoprotein E polymorphism and treatment of alzheimer's disease
GB9408465D0 (en) * 1994-04-27 1994-06-22 Univ Mcgill Apolipoprotein e polymorphism & treatment of alzheimer's disease
US6022683A (en) * 1996-12-16 2000-02-08 Nova Molecular Inc. Methods for assessing the prognosis of a patient with a neurodegenerative disease
US5767337A (en) * 1995-07-31 1998-06-16 Duke University Creation of human apolipoprotein E isoform specific transgenic mice in apolipoprotein deficient "knockout" mice
GB9525481D0 (en) * 1995-12-13 1996-02-14 Royston M C Novel method
ES2115553B1 (es) * 1996-10-23 1999-02-16 Boehringer Ingelheim Espana Metodo para detectar la presencia de polimorfismos de dna, estuche de ensayo y acidos nucleicos recombinantes correspondientes.
FR2765591B1 (fr) * 1997-07-01 2002-08-09 Pasteur Institut Procede de diagnostic de la maladie d'alzheimer
EP1017375A2 (de) * 1997-09-24 2000-07-12 Nova Molecular, Inc. Methoden zum erhöhen des apoe-spiegels zur behandlung von neurodegenerativen krankheiten
ES2142248B1 (es) * 1997-11-20 2000-11-16 Univ Madrid Autonoma Polimorfismos en el promotor del gen humano de la apolipoproteina e, y sus usos para aplicaciones diagnosticas y terapeuticas.
US6251587B1 (en) 1997-12-16 2001-06-26 Nova Molecular, Inc. Method for determining the prognosis of a patient with a neurological disease
WO1999058640A2 (en) 1998-05-11 1999-11-18 Philadelphia Health And Education Corporation Mct-1, a human oncogene
WO2000020634A1 (en) 1998-10-01 2000-04-13 Nova Molecular, Inc. Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of a variant gpiiia and/or variant gpiib allele
US20040209849A1 (en) * 1998-11-27 2004-10-21 Sanochemia Pharmazeutika Aktiengesellschaft Use of effectors of the central cholinergic nervous system for treatment of delirium
US6573049B1 (en) 1999-07-26 2003-06-03 Nuvelo, Inc. Genotyping of the paraoxonase 1 gene for prognosing, diagnosing, and treating a disease
US6432643B1 (en) * 1999-10-22 2002-08-13 Duke University Method of determining Alzheimer's disease risk using apolipoprotein E4 genotype analysis in combination with decreased estrogen levels
EP1113081A1 (de) * 1999-12-28 2001-07-04 Institut Pasteur De Lille Zusammenhang des bekannten Gens CP2/LSF/LBP-1 mit Alzheimer
US6453244B1 (en) * 2000-02-10 2002-09-17 Stanford University Detection of polymorphisms by denaturing high-performance liquid chromatography
US20020133495A1 (en) * 2000-03-16 2002-09-19 Rienhoff Hugh Y. Database system and method
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
PT1292294E (pt) * 2000-05-01 2009-06-01 Accera Inc Utilização de triglicéridos de cadeia média para tratamento e prevenção da doença de alzheimer
US20020010552A1 (en) * 2000-05-26 2002-01-24 Hugh Rienhoff System for genetically characterizing an individual for evaluation using genetic and phenotypic variation over a wide area network
WO2002064735A2 (en) * 2001-02-12 2002-08-22 Akzo Nobel N.V. Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20040005566A1 (en) * 2002-07-02 2004-01-08 Genelink, Inc. Kits and methods for assessing cardiovascular health
WO2006008119A1 (en) 2004-07-16 2006-01-26 Proteosys Ag Muscarinic antagonists with parp and sir modulatng activity as agents for inflammatory diseases
PT2500017T (pt) 2006-04-03 2017-11-14 Accera Inc Utilização de compostos cetogénicos para tratamento de comprometimento da memória associado à idade
WO2008060400A2 (en) * 2006-11-15 2008-05-22 Sirtris Pharmaceuticals, Inc. Sirtuin polymorphisms and methods of use thereof
CA3078084C (en) 2007-07-31 2023-08-15 Cerecin Inc. Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
WO2010003114A1 (en) * 2008-07-03 2010-01-07 Neuera Pharmaceuticals, Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
US8105809B2 (en) * 2008-07-03 2012-01-31 Accera, Inc. Enzymatic synthesis of acetoacetate esters and derivatives
EP2387405A2 (de) 2009-01-13 2011-11-23 ProteoSys AG Pirenzepin als mittel für die krebstherapie
US20110177061A1 (en) 2009-07-10 2011-07-21 Martek Biosciences Corporation Methods of treating and preventing neurological disorders using docosahexaenoic acid
CN110268269A (zh) * 2016-12-18 2019-09-20 赛隆特拉有限公司 使用apoe4基序介导的基因以用于诊断和治疗阿尔茨海默氏病
EP3628315A1 (de) 2018-09-28 2020-04-01 Université de Caen Normandie Kombination aus acetylcholinesterase-inhibitor und 5-ht4-rezeptoragonist als neuroprotektives mittel zur behandlung von neurodegenerativen krankheiten

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009155A1 (en) * 1992-10-13 1994-04-28 Duke University Methods of detecting alzheimer's disease
CA2161538A1 (en) * 1993-07-22 1995-02-02 S. Shirley Yang Controlled release tacrine drug delivery systems and methods for preparing same
US5643960A (en) * 1994-04-15 1997-07-01 Duke University Method of delaying onset of alzheimer's disease symptoms
GB9408465D0 (en) * 1994-04-27 1994-06-22 Univ Mcgill Apolipoprotein e polymorphism & treatment of alzheimer's disease
GB9415073D0 (en) * 1994-06-27 1994-09-14 Smithkline Beecham Plc Novel method
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
GB9414624D0 (en) * 1994-07-20 1994-09-07 Smithkline Beecham Plc Novel method

Also Published As

Publication number Publication date
JPH10500288A (ja) 1998-01-13
AU2300695A (en) 1995-11-16
FI964284A0 (fi) 1996-10-24
DE69531557D1 (de) 2003-09-25
FI964284L (fi) 1996-12-23
JP3285585B2 (ja) 2002-05-27
ATE247717T1 (de) 2003-09-15
NO964543D0 (no) 1996-10-25
WO1995029257A2 (en) 1995-11-02
US5935781A (en) 1999-08-10
GB9408465D0 (en) 1994-06-22
CA2188933A1 (en) 1995-11-02
DE69531557T2 (de) 2004-06-17
FI964284A7 (fi) 1996-12-23
NZ284412A (en) 2000-01-28
CA2188933C (en) 2000-11-14
MX9605176A (es) 1998-06-30
AU693193B2 (en) 1998-06-25
WO1995029257A3 (en) 1995-11-23
EP0804615B1 (de) 2003-08-20
EP0804615A1 (de) 1997-11-05

Similar Documents

Publication Publication Date Title
NO964543D0 (no) Apolipoprotein E polymorfisme og behandling av Alzheimers sykdom
Mérel et al. Screening for germ‐line mutations in the NF2 gene
Wellenreuther et al. Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma
DE69729473D1 (de) Pharmazeutisch-genetische verfahren zur verwendung bei der behandlung von krankheiten des nervensystems
AU8132194A (en) Single nucleotide polymorphisms and their use in genetic analysis
O'Neill et al. A gene for autosomal dominant late-onset progressive non-syndromic hearing loss, DFNA10, maps to chromosome 6
GB9411671D0 (en) Tumor diagnosis and prognosis
ATE209684T1 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
DE60126495D1 (de) Nukleinsäure und protein, genannt 158p1d7, für die behandlung und erkennung von blasenkrebs und anderen krebsarten
EP0756488A4 (de) Tumor-suppressor-gen und verfahren zum nachweis von krebs
Raza et al. A novel homozygous nonsense mutation in the PVRL4 gene and expansion of clinical spectrum of EDSS1
DE69705936D1 (de) Teil der intronsequenz des von hippel-lindau(vhl)-gens und seine verwendung zur krankheitsdiagnose
DE69204157D1 (de) Verfahren zur bestimmung von anti-rns-antikörpern.
WO2001004349A3 (en) Method for the diagnosis or the prognosis of alzheimer disease therapeutical composition for preventing or treating alzheimer disease
AU2904197A (en) Diagnostic method and apparatus based on polymorphism in an IL-6 gene
DE59509370D1 (de) Mittel zur beeinflussung von störungen der knochenbildung, das kaliumcitrate und/oder kaliumlactate und/oder kaliummalate enthält
Rauramaa et al. The Rsal Polymorphism in the α-Fibrinogen Gene and Response of Plasma Fibrinogen to Physical Training
DK0870036T3 (da) Syntetisk pattedyrs-alfa-N-acetylglucosaminidase og genetiske sekvenser kodende derfor
AU2002358580A1 (en) Methods of identifying genetic risk for and evaluating treatment of alzheimer's disease by determing single nucleotide polymorphisms
HAN et al. Prognostic implication of trisomy 12 and non-trisomy 12 karyotypes in B cell chronic lymphocytic leukemia
DE69734890D1 (de) Rdgb-proteine
DE60224778D1 (de) Zusammensetzungen und Verfahren zur Behandlung und zur Detektion von proliferativen Störungen die mit der Überexpression des menschlichen "Transketolase like-1" gens in Zusammenhang stehen
Zhang et al. Elastin region deletions in Williams syndrome
RU2195676C2 (ru) Способ комплексной оценки прогноза эффективности лечения диффузных заболеваний соединительной ткани низкомолекулярными антикоагулянтами
Song et al. Presence of 844ins68 in the Cystathionine β-Synthase Gene in Asians (Koreans)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application